OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Poster presentation to reveal data regarding in vivo efficacy against patient-derived xenografts (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) Taipei, Taiwan, October 24, 2017 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that new data, for OBI-3424 in vivo efficacy against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL), […]